Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Sagimet Biosciences Phase 3 Trial of Denifanstat as Acne Treatment Has High Success Probability, Wedbush Says

Sagimet Biosciences Phase 3 Trial of Denifanstat as Acne Treatment Has High Success Probability, Wedbush Says

MT newswireMT newswire2026/10/01 15:32
11:32 AM EDT, 10/01/2026 (MT Newswires) -- Sagimet Biosciences' (SGMT) planned phase 3 study of denifanstat as acne treatment should have a high probability of success based on previous clinical data and expert opinion, Wedbush Securities said in a Thursday note. Wedbush said the product candidate continued to demonstrate improvement across all co-primary endpoints and key secondary endpoints after the main 12-week treatment period and adverse effects were consistent overall. Denifanstat has the potential to be approved as a front-line therapy for moderate to severe acne, based on its mechanism of action that normalizes sebum production, along with strong safety and tolerability, the brokerage noted. Top-line data from the phase 3 study could be ready by year-end 2027 to back a new drug application in 2028, Wedbush added. Wedbush has an outperform rating and $28 price target on Sagimet Biosciences. Price: 9.49, Change: -0.40, Percent Change: -4.00
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Masayoshi Son's Trillion-Dollar Gamble: Once Considered Acquiring SK Hynix

According to reports, Masayoshi Son once planned to acquire the South Korean memory chip giant SK Hynix for nearly 1 trillion US dollars and had approached Wall Street institutions to seek financing, but SoftBank has confirmed it is no longer actively pursuing the deal. The massive financing requirement and South Korean regulatory restrictions were major obstacles. This plan also highlights SoftBank’s further strategic intention to invest in AI storage chips.

华尔街见闻•2026/11/21 03:16

"Sell-offs bring more sell-offs! Goldman Sachs predicts another large-scale sell-off in the U.S. stock market in the coming week."

Goldman Sachs stated that the bank’s “panic index” has risen to 9 out of 10, with systemic selling pressure continuing to spread. In the coming week, CTAs may sell up to $80.6 billion in US stocks, and even if the market remains flat, there is still $65.8 billion in sell orders waiting to be executed. The Anthropic IPO failed to boost market risk appetite, and concerns over AI investment returns continue to weigh on tech stock valuations.

华尔街见闻•2026/11/21 02:16